Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke) [Clinical Sciences]

Conclusions—In patients treated with r-tPA, adjunctive argatroban was not associated with increased risk of symptomatic intracerebral hemorrhage and provides evidence that a definitive effectiveness trial is indicated.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01464788.

Source: Stroke - May 22, 2017 Category: Neurology Authors: Andrew D. Barreto, Gary A. Ford, Loren Shen, Claudia Pedroza, Jon Tyson, Chunyan Cai, Mohammad H. Rahbar, James C. Grotta, on behalf of the ARTSS-2 Investigators Tags: Clinical Studies, Cerebrovascular Disease/Stroke, Ischemic Stroke, Thrombosis Original Contributions Source Type: research